Company Filing History:

11 out of 42

La Jolla Pharmaceutical Company

La Jolla Pharmaceutial Company

patent

Years Active: 1990-2008

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7351855 - Chemically defined non-polymeric valency platform molecules and conjugates thereof (2008-04-01),

2. 7115581 - Chemically-defined non-polymeric valency platform molecules and conjugates thereof (2006-10-03),

3. 6060056 - Composition for inducing humoral anergy to an immunogen comprising a T (2000-05-09),

4. 5874552 - Modified phosphorous intermediates for providing functional groups on (1999-02-23),

5. 5786512 - Modified phosphorous intermediates for providing functional groups on (1998-07-28),

6. 5726329 - Modified phosphorous intermediates for providing functional groups on (1998-03-10),

7. 5633395 - Chemically-defined non-polymeric valency platform molecules and (1997-05-27),

8. 5606047 - Chemically-defined non-polymeric valency platform molecules and (1997-02-25),

9. 5552391 - Chemically-defined non-polymeric valency platform molecules and (1996-09-03),

10. 5391785 - Intermediates for providing functional groups on the 5' end of (1995-02-21),

11. 5276013 - Conjugates of biologically stable polyfunctional molecules and (1994-01-04),

12. 5162515 - Conjugates of biologically stable polymers and polynucleotides for (1992-11-10),

13. 5019573 - Substituted dibenzofurans and methods of using same (1991-05-28),

14. 4956371 - Substituted isoquinolines and methods of using same (1990-09-11),

Title: The Innovative Contributions of Stephen M Coutts

Introduction

Stephen M Coutts is a prominent inventor based in Rancho Santa Fe, California. He holds an impressive portfolio of 14 patents, showcasing his significant contributions to the field of biotechnology. His work primarily focuses on the development of chemically defined non-polymeric valency platform molecules, which have important applications in medical research.

Latest Patents

Coutts' latest patents include groundbreaking innovations such as "Chemically defined non-polymeric valency platform molecules and conjugates thereof." This patent describes chemically-defined, non-polymeric valency platform molecules and conjugates that comprise biologically or chemically relevant molecules, including polynucleotide duplexes of at least 20 base pairs. These molecules exhibit significant binding activity for human lupus anti-dsDNA autoantibodies, highlighting their potential in therapeutic applications.

Career Highlights

Throughout his career, Coutts has worked with notable companies, including La Jolla Pharmaceutical Company and Euro-Celtique S.A. His experience in these organizations has allowed him to refine his expertise and contribute to innovative projects that advance the field of biotechnology.

Collaborations

Coutts has collaborated with esteemed colleagues such as David S Jones and Douglas Alan Livingston. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and the development of cutting-edge technologies.

Conclusion

Stephen M Coutts is a distinguished inventor whose work in the field of biotechnology has led to significant advancements. His patents and collaborations reflect his commitment to innovation and the pursuit of solutions for complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.